Previously, we showed that DTNQ-Pro acts on two major targets involved in the resistance of CRC cells to chemotherapy agents: the process of cell differentiation and overexpression of HSP family proteins [26]. This evidence concerns the gene HSP90B2P and colorectal carcinoma.